Amal Therapeutics SA announces appointment of Johanna Holldack as Chairman
Amal Therapeutics SA, a Swiss and German-based company focusing on the development of therapeutic cancer vaccines, announced today the appointment of Dr Johanna Holldack as chairman of the board. Dr Holldack brings over 20 years experience in Biotechnology and Drug Development.
Dr. Holldack has worked in the pharmaceutical industry for more than 20 years, where she has held key positions in both start-up and large pharma companies. Her experience includes management and executive positions at Behringwerke, Chiron, MediGene and Borean Pharma. She is currently CEO and member of the board of Telormedix.
Dr. Holldack has a medical degree from Georg-August-University in Gottingen, Germany and is a Board Certified pediatrician. In addition, she has held positions as an assistant professor at the University of Essen, research fellow for the Deutsche Krebshilfe and a research associate at Harvard Medical School.
Dr Madiha Derouazi, CEO of Amal Therapeutics, says: ”I am delighted that Dr Holldack is joining our board. She brings with her considerable knowledge in drug development, and her experience is an important asset for Amal Therapeutics.”
About Amal Therapeutics SA Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology.
Please login or sign up to comment.
Commenting guidelines